Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hiroshi Ishiguro
Observed name:
HIROSHI ISHIGURO
Institutions:
Saitama International Medical Center,
Saitama Medical University
Observed institutions:
Saitama International Medical Center,
Saitama Medical University
ORCID:
0000-0002-9859-5932
Observed ORCID:
0000-0002-9859-5932
OpenAlex ID:
A5123973607
Real-world treatment patterns and outcomes in older patients with metastatic breast cancer: a multi-institutional retrospective cohort study
2026
·
Reiko Mitsueda
, Yasuaki Sagara
, et al.
·
Breast Cancer Research and Treatment
·
2
PDF
Association between tumor-infiltrating lymphocytes and oncotype DX estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 single gene scores in hormone receptor-positive/HER2-negative breast cancer
2026
·
Masahiro Ohara
, Emi Mikami
, et al.
·
Frontiers in Oncology
·
2
PDF
Baseline Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival in PD-L1-positive Advanced Triple-negative Breast Cancer With Immune-checkpoint-inhibitor Treatment
2026
·
AKIHIRO FUJIMOTO
, YUKI ICHINOSE
, et al.
·
Cancer Diagnosis & Prognosis
·
1
PDF
Occult breast cancer showing a marked response to pembrolizumab plus gemcitabine and carboplatin therapy complicated by immune‑related colitis: A case report
2026
·
Wakako Inohana
, Masahiro Ohara
, et al.
·
Molecular and Clinical Oncology
·
1
PDF
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
2026
·
Yukinori Ozaki
, Shohei Koyama
, et al.
·
BMJ Open
·
1
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study
2026
·
Norikazu Masuda
, Hiroyuki Yasojima
, et al.
·
Breast Cancer Research and Treatment
·
1
PDF
E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114
2026
·
Hiroshi Ishiguro
, Yasuo Miyoshi
, et al.
·
Breast Cancer Research
PDF
Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy
2026
·
Akihiro Fujimoto
, Yuki Ichinose
, et al.
·
Clinical Breast Cancer
Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan
2026
·
Akihiro Fujimoto
, Yuki Ichinose
, et al.
·
BMC Cancer
Compartment-Specific CD138 Expression Defines an Aggressive Breast Cancer Phenotype with Distinct Transcriptomic Features
2026
·
Kyoko Asai
, Takahiro Hasebe
, et al.
·
Cancers
PDF
Septic Pulmonary Embolism due to Methicillin-Resistant Staphylococcus aureus Bacteremia during Adjuvant Chemotherapy for Breast Cancer: A Case Report
2026
·
Aya Asano
, Masafumi Seki
, et al.
·
Case Reports in Oncology
PDF
Show more works
View as search
Works count:
11
Citation count:
8
H-index:
2
I10-index:
Year
Topic
Type